NEOGENOMICS INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $727.3M | $660.6M | $591.6M | $509.7M | $484.3M |
| Gross profit | $314.3M | $290.1M | $244.6M | $187.9M | $187.1M |
| Operating income | -$115.9M | -$92.1M | -$107.7M | -$157.6M | -$118.8M |
| Operating expenses | $430.2M | $382.2M | $352.3M | $345.5M | $305.8M |
| Cost of revenue | $413.0M | $370.5M | $347.0M | $321.8M | $297.3M |
| Cash from operations | $5.2M | $7.0M | -$2.0M | -$66.0M | -$26.7M |
| Capital expenditure | $27.0M | $41.1M | $28.8M | $30.9M | $64.1M |
| Free cash flow | -$21.8M | -$34.0M | -$30.7M | -$96.9M | -$90.9M |
| Impairments | $3.5M | $0 | $0 | $718,000 | $0 |
| Total assets | $1.4B | $1.6B | $1.7B | $1.7B | $1.9B |
| Total liabilities | $523.3M | $735.7M | $739.7M | $742.0M | $761.5M |
| Total debt | $345.0M | $546.2M | $538.2M | $535.4M | $533.7M |
Shares outstanding 130.2M · Free float 81.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.